V1RD19 Inhibitors
V1RD19 inhibitors pertain to a chemical class designed to intervene at a molecular level with specific biological pathways. This class of compounds is characterized by their ability to bind to the active or allosteric sites of the V1RD19 protein, leading to a modulation of its activity. The inhibitors are meticulously engineered to fit the unique topology of the V1RD19's binding regions, which often involves a high degree of specificity to ensure that their interaction with the target protein is both effective and selective. The chemical structure of these inhibitors is diverse, ranging from small molecules to more complex biologics, depending on the nature of the V1RD19 protein and the desired outcome of the inhibition.
The development of V1RD19 inhibitors is a complex process that involves an in-depth understanding of the protein's role at the cellular or systemic level. Researchers utilize various techniques such as X-ray crystallography, computational modeling, and structure-activity relationship (SAR) studies to identify and optimize potential inhibitors. These compounds often arise from iterative processes involving the synthesis and modification of molecular structures to improve binding affinity and specificity. The specificity is paramount, as off-target effects can lead to unintended interactions with other proteins. Therefore, a considerable amount of research is dedicated to understanding the precise conformation of the V1RD19 protein, its dynamics, and the potential for cross-reactivity. This research provides the foundational knowledge necessary to design inhibitors that can effectively modulate the function of the protein without affecting similar proteins within the biological system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that blocks epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting EGFR, it may downregulate V1RD19 by suppressing the downstream signaling pathways that V1RD19 is involved in, leading to reduced proliferation and survival signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that interferes with the mTOR (mammalian target of rapamycin) signaling pathway. As mTOR is critical for cell growth and metabolism, inhibiting this pathway could decrease the activity of V1RD19 if it is associated with these cellular processes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple tyrosine kinases, such as VEGFR and PDGFR, and the Raf kinases involved in the MAPK signaling pathway. Inhibition of these pathways could lead to a reduction in the functional activity of V1RD19 if it is reliant on these signaling cascades for activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that affects chromatin remodeling and gene expression. By altering gene expression patterns, it could downregulate V1RD19 if its expression is controlled by acetylation status. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents phosphatidylinositol 3-kinase (PI3K) from phosphorylating AKT, leading to a decrease in the PI3K/AKT/mTOR pathway activity. If V1RD19 is functionally dependent on this pathway, its activity would be inhibited. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is an EGFR inhibitor that is selective for mutant forms of the receptor. It could downregulate V1RD19 by inhibiting EGFR-driven pathways that might contribute to the regulation or activity of V1RD19. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a potent inhibitor of Raf-1 kinase, which could decrease MAPK/ERK signaling. As a result, if V1RD19 function is connected to this pathway, GW5074 could indirectly lead to its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is involved in stress and inflammatory responses. Inhibition of JNK could lead to the downregulation of V1RD19 if it is implicated in these responses. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway, which could lead to reduced activity of V1RD19 if it is linked to the MAPK/ERK pathway for its activation or regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor, similar to PD98059, and it works by blocking the activation of MAPK/ERK pathway. This could lead to the inhibition of V1RD19 if it is regulated by or dependent on this pathway. | ||||||